Skip to main content

CORRECTION article

Front. Immunol., 07 November 2022
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1074864

Corrigendum: Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy

This article is a correction to:

  1. Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy

    1. Read original article
Jianping Wu&#x;Jianping Wu†Xiaona Wei&#x;Xiaona Wei†Jiajia LiJiajia LiYangang GanYangang GanRui ZhangRui ZhangQianqian HanQianqian HanPeifen LiangPeifen LiangYuchun ZengYuchun ZengQiongqiong Yang*Qiongqiong Yang*
  • Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

A corrigendum on
Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy

by Wu J, Wei X, Li J, Gan Y, Zhang R, Han Q, Liang P, Zeng Y and Yang Q (2022) Front. Immunol. 13:978315. doi: 10.3389/fimmu.2022.978315

In the published article, the funding information was missing. The correct Funding statement appears below.

Funding

This project was funded by the National Key R&D Programme of China (2021YFC2009404); the Science and Technology Projects in Guangzhou (201904010142) and the Natural Science Foundation of Guangdong Province (2021A1515010801).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: IgA nephropathy, Renin-angiotensin system inhibitors, Exosome, Biomarker, Treatment response

Citation: Wu J, Wei X, Li J, Gan Y, Zhang R, Han Q, Liang P, Zeng Y and Yang Q (2022) Corrigendum: Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy. Front. Immunol. 13:1074864. doi: 10.3389/fimmu.2022.1074864

Received: 20 October 2022; Accepted: 21 October 2022;
Published: 07 November 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland;

Copyright © 2022 Wu, Wei, Li, Gan, Zhang, Han, Liang, Zeng and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qiongqiong Yang, eWFuZ3FxQG1haWwuc3lzdS5lZHUuY24=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.